PBYI News and Press, Puma Biotechnology Inc From 02/16/22

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 3, following release of its fourth quarter and full year 2021 financial results. The call may be accessed by dialing 1-877-709-8150 (do...

Puma Biotechnology (NASDAQ:PBYI) has announced that the Compensation Committee of Puma’s Board approved the grant of inducement restricted stock unit awards covering an aggregate of 24,375 shares of Puma common stock to three new non-executive employees. The restricted stock unit award...

3 Premarket Gaining Penny Stocks to Watch Right Now With blue chips and penny stocks climbing slightly during premarket, investors are excited about the future. The recent movement could be due to the better-than-expected CPI news from last month. Prior to this, we were witnessing major...

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of breast cancer have been updated for 2022 and include two important change...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, presented at the virtual H.C. Wainwright BioConnect Conference, which began at 7:00 a.m. EST on Monday...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be...

Neratinib in combination with fulvestrant and trastuzumab offers promising results for patients with hormone receptor-positive, HER2-mutated metastatic breast cancer with prior exposure to CDK4/6 inhibitors Neratinib in combination with trastuzumab results in strong activity...

Gainers: MediciNova (NASDAQ:MNOV) +27%. Puma Biotechnology (NASDAQ:PBYI) +6%. GoHealth (NASDAQ:GOCO) +5%. Chindata Group Holdings Limited (NASDAQ:CD) +4%. Nutanix (NASDAQ:NTNX) +4%. Losers: Autodesk (NASDAQ:ADSK) -13%. Esperion Therapeutics (NASDAQ:ESPR) -10%. Cl...

Puma Biotechnology (NASDAQ:PBYI) announced that the U.S. regulators have extended the term of a patent related to the company’s breast cancer therapy NERLYNX by five years. The United States Patent and Trademark Office (USPTO) has extended the validity period of U.S. Patent No. 7,399,8...

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) issued a Patent Term Extension Certificate for U.S. Patent No. 7,399,865, extending the patent term five (5) years. The patent includes composition ...